AscellaHealth Establishes International Strategic Advisory Council, Enhances Global Life Sciences Support Services Amid Regulatory and Market Complexity
Globe Newswire • Tue Jun 09 2026
AscellaHealth announces the formation of its international Strategic Advisory Council (ASAC), bringing together global expertise to guide Life Sciences companies in navigating complex markets and accelerating access to rare disease therapies.
DUBLIN and BERWYN, Pa., June 09, 2026 (GLOBE NEWSWIRE) – AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces the formation of its international Strategic Advisory Council (ASAC), bringing together global expertise to guide Life Sciences companies in navigating complex markets and accelerating access to rare disease therapies. ASAC is established to reinforce AscellaHealth’s strategic leadership across the specialty pharmaceutical value chain, shaping pivotal decisions that drive operational excellence, cost efficiency and market impact as next-generation therapies transform the global landscape.
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.